Table 1.
Characteristics of the patient population.
| Total N (%) | Liquid Assay in hospital (%) | Liquid Assay at home (%) | |
|---|---|---|---|
| Age | |||
| Median | 63 | 63 | 63 |
| Mean | 61.5 | 61.3 | 61.8 |
| Gender | |||
| Female | 168 (42%) | 101 (41%) | 67 (44%) |
| Male | 231 (58%) | 145 (59%) | 86 (56%) |
| Race | |||
| Caucasian | 399 | 246 | 153 |
| ECOG PS | |||
| 0 | 146 (36.6%) | 107 (43.6%) | 39 (25.5%) |
| 1 | 210 (52.6%) | 116 (47.1%) | 94 (61.5%) |
| 2 | 38 (9.5%) | 21 (8.5%) | 17 (11.1%) |
| 3 | 5 (1.3%) | 2 (0.8%) | 3 (1.9%) |
| Systemic anti-cancer therapies at the time of the test | |||
| Before/after radical surgery/adjuvant | 30 (7.5%) | 24 (10%) | 6 (4%) |
| First line | 188 (47.1%) | 107 (43%) | 81 (53%) |
| Second line | 50 (12.6%) | 27 (11%) | 23 (15%) |
| Advanced lines | 131 (32.8%) | 88 (36%) | 43 (28%) |
| Tumor samples types | |||
| CRC | 150 (37.6%) | 90 (37%) | 60 (39.2%) |
| NSCLC | 103 (25.8%) | 52 (21%) | 51 (33.3%) |
| GC | 52 (13%) | 41 (16.5%) | 11 (7.2%) |
| PC | 15 (3.7%) | 8 (3.2%) | 7 (4.5%) |
| BTC | 3 (0.7%) | 2 (0.8%) | 1 (0.6%) |
| BC | 19 (4.7%) | 11 (4.5%) | 8 (5.4%) |
| Others | 57 (14.5%) | 42 (17%) | 15 (9.8%) |
Abbreviations: CRC, colorectal cancer; NSCLC, non-small cell lung cancer; GC, gastrointestinal cancer; PC, pancreatic cancer; BTC, biliary tract cancer; BC, breast cancer; ECOG PS: Eastern Cooperative Oncology Group Performance Status; N, number.